SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, a high pretherapeutic OCT1 expression predicts a complete molecular response to the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) [14].